Eugenia Girda
Rutgers, The State University of New Jersey
H-index: 13
North America-United States
Top articles of Eugenia Girda
A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors, including …
2024/1/20
Completed durable response of advanced endometrial cancer treated with pembrolizumab without surgical intervention or systemic chemotherapy: A case report
Current Problems in Cancer: Case Reports
2024/6/1
Eugenia Girda
H-Index: 7
Abstract CT265: Trastuzumab emtansine in patients (pts) with HER2 mutation-positive (HER2mut) tumors: TAPISTRY study
Cancer Research
2024/4/5
308 A randomized, double-blind, phase 2 study of MK-4280A (coformulation of favezelimab and pembrolizumab) plus lenvatinib vs pembrolizumab plus lenvatinib in patients with …
2024/3/1
A Report of a Rare Case of Rapidly Progressing Immature Teratoma With Associated Splenic Metastasis and Gliomatosis Peritonei
Cureus
2024/2/12
Eugenia Girda
H-Index: 7
Personalized Versus Precision Nanomedicine for Treatment of Ovarian Cancer
Small
2024/2/11
Eugenia Girda
H-Index: 7
Tamara Minko
H-Index: 40
Cervical cancer treatment update: A Society of Gynecologic Oncology clinical practice statement
Gynecologic oncology
2023/12/1
Eugenia Girda
H-Index: 7
Disparities in brachytherapy utilization in cervical cancer in the United States: A comprehensive literature review
2023/12/1
LBA43 Updated response data and analysis of progression free survival by mechanism of mismatch repair loss in endometrial cancer (EC) patients (pts) treated with pembrolizumab …
Annals of Oncology
2023/10/1
1039P First-in-human phase I study of givastomig, a novel Claudin 18.2/4-1BB bispecific antibody in advanced solid tumors
Annals of Oncology
2023/10/1
Pembrolizumab versus placebo in addition to carboplatin and paclitaxel for measurable stage 3 or 4a, stage 4b or recurrent endometrial cancer: The phase 3, NRG GY018 study (LBA 10)
Gynecologic oncology
2023/9/1
Real life utilization of sentinel lymph node mapping in endometrial cancer: Patterns of practice in unmapped patients and effect on treatment and outcomes (1218)
Gynecologic Oncology
2023/9/1
Ruth Stephenson
H-Index: 0
Eugenia Girda
H-Index: 7
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers
International Journal of Gynecologic Cancer
2023/8/1
Challenges in treatment of gestational trophoblastic neoplasia in patients with MTHFR mutation: A case report
Gynecologic Oncology Reports
2023/8
Eugenia Girda
H-Index: 7
Publication rates of podium presentations at the Society of Gynecologic Oncology (SGO) annual meetings
2023/8/1
Eugenia Girda
H-Index: 7
Pembrolizumab plus chemotherapy in advanced endometrial cancer
New England Journal of Medicine
2023/6/8
Eugenia Girda
H-Index: 7
A phase 1 study of fianlimab (anti-LAG-3) in combination with cemiplimab (anti-PD-1) in patients with advanced melanoma: Poor-prognosis subgroup analysis.
2024/2/1
Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.
2023/6/1
Eugenia Girda
H-Index: 7
Fang Fang
H-Index: 36
A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors
European Journal of Medical Research
2022/7/2
Using pan-sarcoma multiomic analysis for identifying sarcoma subtypes with immunogenic potential.
2022/6/1
